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ess: chetta@unipr.it (A.Summary In 102 healthy Caucasians, 20–50 years old, we investigated the effect
of anthropometrics on the 6-min walk test (6MWT), in order to provide reference
values for walk distance (6MWD), oxygen saturation (SpO2), pulse rate (PR),
respiratory rate (RR), breathlessness perception (VAS) and for the walking distance
and body weight product (DW).
The mean 6MWD and DW values were 593757 and 638744m (Po0.01) and
35,03075306 and 48,88276555 kgm (Po0.01), respectively for women and for
men. While walking, SpO2 remained unaltered and subjects reached 67710% of their
maximal predicted heart rate and a RR mean value of 1974 bpm. VAS ratings were
significantly higher in females as compared to males (24715 vs. 1875mm,
Po0.05), however, when corrected for PR change while walking, they were not
different. The equation by stepwise multiple regression analysis included height, age
and gender for the 6MWD and accounted for 42% of the total variance.
This study confirms the relevant effect of anthropometrics on walking capacity
and suggests that when rating dyspnea, the change in heart rate during walking
should be considered.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Chetta).Introduction
In the last decade, the 6-min walk test (6MWT) has
been increasingly used to assess functional exercise
performance across various patient populations.1–8
The 6MWT is self-paced, and involves measuring the
distance a patient can walk on a level course ined.
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its simplicity and that it does not require sophisti-
cated equipment and can be easily performed by
even the most severely debilitated patients. More-
over, the 6MWT better reflects activities of daily
living than other walk tests.10 Recently, the
American Thoracic Society developed guidelines
for the 6MWT in clinical settings.11
In healthy subjects, the 6-min walk distance
(6MWD) ranges from 400 to 700m, the main
predictor variables being gender, age and
height.12–14 However, the few published studies
have all used different methods, and the predicted
distances differ by up to 30%.15 Furthermore,
although 6MWT performance has been assessed
even in patients at relatively young age, such as
those with interstitial lung disease,3 cystic fibrosis,4
obesity,6 or HIV-associated wasting,8 only one study
14 published reference values for the 6MWD for
subjects 20–40 years old.
Accordingly, the aim of the present study was to
investigate in healthy subjects, 20–50 years old, the
effect of demographics and anthropometrics on the
6MWT, performed according to the standardized
approach provided by the ATS guidelines.11 Further-
more, we aimed to provide reference values in such
subjects for the 6MWD and other primary variables
measured in the 6MWT, such as oxygen saturation
(SpO2), pulse rate (PR), respiratory rate (RR), and
breathlessness perception. In this study, we also
considered a derived variable of the 6MWT, the
product of walking distance and body weight (DW),
which is considered to mimic the work of walking.16Methods
Subjects
We studied a sample of 102 healthy subjects (54
females) from all decades of age between 20 and 50
years (mean7standard deviation (SD) age: 3479
years). They were volunteers recruited from the
University campus and from the surrounding com-
munity. All subjects were free from injury and had
no history of hospitalization or chronic disease
influencing their exercise capacity. Moreover, they
were not involved in any competitive sport and
they were lifetime non-smokers. All subjects gave
informed consent to participate in the study.
Lung function test
Lung function was measured by a flow-sensing
spirometer and a body plethysmograph connectedto a computer for data analysis (Vmax 22 and 6200,
Sensor Medics, Yorba Linda, USA). Baseline total
lung capacity (TLC), forced expiratory volume in 1 s
(FEV1), vital capacity (VC), and FEV1/VC ratio were
recorded. Carbon monoxide transfer capacity
(TLCO) was measured by the single breath method
and considered valid only if the inspiratory volume
was at least 90% of VC. At least three measure-
ments were made for each lung function variable to
ensure reproducibility. Predicted values of lung
volumes and expiratory flows as well as TLCO were
obtained from regression equations by Quanjer et
al.17 and Cotes et al., 18 respectively.Six-min walk test
After lung function testing, all subjects performed
two 6MWTs according to a standard protocol.11 All
subjects received the same instructions before the
walk and were encouraged by the investigator who
repeated set phrases every 30 s during the walk.
Each subject underwent the 6MWT in an undis-
turbed 30-m indoor, level, hospital corridor. The
second 6MWTwas performed in the same manner as
the first, following a rest of at least 60min. The
6MWD covered during the test was recorded in
meters. Results from the second walk were only
used for analysis to allow for any learning effect.19
Before and immediately after the 6MWT, all
subjects rated the magnitude of their perceived
breathlessness on an interval scale, which was a
100-mm horizontal visual analogue scale (VAS).20
The VAS consisted of a horizontal ruler without any
mark on the subject’s side with the words ‘‘not at
all breathless’’ and ‘‘extremely breathless’’ on the
left and right end, respectively. The subject had to
indicate his breathlessness perception at the
moment of the assessment, by moving a marker
along the ruler. Breathlessness perception ratings
were expressed in mm from 0 to 100 and
corresponded to the distance of the marker from
the left end of the VAS. In each subject, resting and
after-walk RR (bpm) were also recorded before and
immediately after the 6MWT.
The SpO2 (%) and PR (bpm) were continuously
monitored from 5min before the walk until test
completion, as well as 5min after completion, or
until recovery of the baseline value by using a
lightweight (0.3 kg) portable pulse oximeter
(Healthdyne, Model 920M, Marietta, GA, USA). This
device was carried by each subject with a shoulder
strap and a finger probe and was applied to the
non-dominant hand. The oxygen saturation and
heart rate readings were recorded in the oximeter
memory every 10 s. For each subject, the resting
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Table 2 Personal details and 6-MWT measures of
the study subjects.
Women (n ¼ 54) Men (n ¼ 48)
Age, years 3379 3678
Height, cm 16477 17677**
Weight, kg 5978 7779**
BMI, kg/m2 2273 2572**
6MWD, m 593757 638744**
DW, kgm 35,03075306 48,88276555**
PR base, bpm 81710 75710**
PR mean, bpm 115718 101717**
PR maximal, bpm 132718 119718**
VAS, mm 24715 18715*
VAS/PRchange 0.6570.41 0.5370.48
Values are expressed as mean7SD; **Po 0.01, *Po 0.05.
Reference values for 6MWT 1575SpO2 values (resting SpO2, %), such as the average
of the SpO2 readings taken before the walk, and the
mean saturation recorded during the walk (walking
SpO2, %) were noted. The resting PR values (resting
PR, bpm) which were the average of the PR
readings taken before the walk, the mean PR
recorded during the walk (walking PR, bpm) and
the maximum PR sustained for more than 10 s
(maximum PR, bpm) during the walk were also
noted. The predicted maximum PR was calculated
by the following equation: 210–0.66 age.21
Statistical analysis
All pulmonary function test results are expressed as
percent of predicted value or as absolute value.
Data are reported as mean7SD and differences in
numerical data between groups were determined
by the unpaired t-test. Furthermore, relationships
were estimated by the Pearson correlation coeffi-
cient (r). Stepwise multiple regression analysis was
used to determine the best predictor variables for
the 6MWT dependent variables. Percentage of total
variance in the dependent variable, accounted for
by the predictor variables, is expressed as the
adjusted square of the multiple correlation coeffi-
cient (r2). A P-value of less than 0.05 was taken as
significant.Results
Lung function values of healthy subjects are
summarized in Table 1. The DW was calculated as
the product of the walk distance (in m)body
weight (in kg).
The mean 6MWD was 614756m, ranging from
459 to 738m, and the mean DW was
41,54879112 kgm, ranging from 26,100 to
66,976 kgm. Oxygen saturation remained unaltered
throughout the walk. Mean resting and walking
SpO2 values were, respectively, 9870.9% and
9771.3%. The mean change in SpO2 was 1.071.1%.
PR and RR were significantly affected by the
walk. Mean resting, walking and maximum PR
values were, respectively, 78711, 108719
(Po0.001 vs. resting values), and 126719 bpmTable 1 Lung function values of the 102 study
subjects.
TLC, % pred 110710
FEV1, % pred 112714
FEV1/VC, % 8276
TLCO, % pred 98714
Values are expressed as mean7SD.(Po0.001 vs. resting values). Moreover, during
the walk, subjects reached 67710% of their
maximal predicted heart rate. Resting and after-
walk RR were, respectively, 1473 and 1974 bpm
(Po0.001). In all subjects, the mean value of
ratings on the VAS after the walk was 21715mm.
Gender significantly affected the 6MWD (Table 2).
On average, the 6MWD and the DW values were 45m
and 13,582 kgm greater in male subjects, when
compared to female subjects. Mean resting, walking
and maximum PR values were significantly higher in
female subjects, as compared to male subjects.
Moreover, ratings on the VAS were significantly higher
in females as compared to males, however, when
corrected for the maximum PR percentage change of
resting PR (VAS/PRchange), there was no difference
between females and males.
In all subjects, the 6MWD was inversely and
directly related, respectively, to age (r ¼ 0.42;
Po0.001) and height (r ¼ 0.46; Po0.001) (Fig. 1).
After-walk VAS was directly related to after-walk
RR (rs ¼ 0.27, Po0.01) and to PR max (rs ¼ 0.24,
Po0.05).
The regression equation generated by stepwise
multiple regression analysis for the 6MWD included
height, age and gender. This model accounted for
42% of the total variance for the 6MWD (Table 3).
Moreover, multiple regression analysis for the
ratings on the VAS after walking could not account
for more than 10% of the total variance, the main
predictor variable being RR after walking.Discussion
The present study provides reference values for the
primary variables measured in the 6MWT in healthy
subjects between 20 and 50 years of age. The
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A. Chetta et al.1576reference values may be useful to interpret 6MWT
performance in patients with significant respiratory
or cardiac dysfunction at a relatively young age,
such as those with cystic fibrosis, obesity, inter-
stitial lung disease, or dilatative cardiomyopathy.
Moreover, the reference values provided by this
study apply to the 6MWT protocol proposed by the
American Thoracic Society guidelines.11 In these
guidelines, some recommendations and suggestions
concerning technical aspects and quality assurance
of the 6MWT are present. Specifically, the recom-
mended length of the corridor is 30m so as to avoidTable 3 Predicting model for walk distance (6MWD, m).
Coefficient Standa
r2 ¼ 0.42
Height 1.250 0.64
Age 2.816 0.49
Gender 39.07 (1 ¼ females, 0 ¼ males) 11.59
Constant 518.853 118.11
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Figure 1 Relationship between 6MWD and age (upper
panel) and height (lower panel) in 102 healthy subjects
20–50 years old. The linear regression line is super-
imposed, surrounded with the 95% confidence interval
lines for the regression line. r ¼ Pearson correlation
coefficient.too many turns during the test, one practice walk
should be considered to allow for the learning
effect and encouragement should be given regu-
larly to ensure maximal motivation and perfor-
mance. In this regard, previous studies did not take
into account some of these methodological aspects
of the 6MWT. For example, in the study by Gibbons
and colleagues,14 a 20-m corridor was used, while
in the study by Enright and Sherrill,12 a practice
test was not performed.
As expected, the present study confirmed that
several demographic and anthropometric factors
can influence the 6MWT performance in healthy
subjects. In our model, gender, height and age can
reliably predict the 6MWD. Intuitively, a taller
height is associated with a longer stride, which
probably results in a longer distance walked by
taller subjects. Moreover, the shorter distance
walked by the older participants in our study may
be explained by changes in skeletal muscles, as
compared to the younger subjects. A gradual
reduction of skeletal muscle mass and strength
has been demonstrated in the elderly,22,23 however
our findings suggest that the decline in skeletal
muscle function could be earlier. Our model can
explain only 40% of the variance in the 6MWD,
which is in agreement with previous reports.12,14
Potential sources of variance other than age,
gender or height should be considered. One
potential source of variance may be the different
attitudes, beliefs as well as the mood of the
participants. Indeed, it has been demonstrated
that psychological status is related to exercise
capacity both in healthy subjects 24 and in patients
with chronic bronchitis.25 Another potential source
of variance may be the different peripheral muscle
conditioning of the participants, since we included
in this study both habitually active and sedentary
healthy subjects.
The DW is a simplification of the equation
proposed by Cavagna and Margaria 26 to determine
the horizontal work on a treadmill and was
proposed by Chuang et al.16 as a measure for
assessing the functional capacity during a 6MWT. In
COPD patients, DW was superior to the 6MWD,
when correlated with oxyhemoglobin saturationrd error P 95% confidence intervals
1 0.05 0.006 2.506
7 0.000 3.790 1.842
2 0.001 61.789 16.349
4 0.000 287.350 750.356
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and maximal oxygen uptake.16 In addition, in a
large group of COPD patients, the DW could
discriminate better than the 6MWD, patients with
low work capacity from those with high work
capacity as assessed by bike ergometry.27 There-
fore, DW is considered to be a measure that reflects
the work of walking better than the 6MWD and is
suggested to evaluate exercise tolerance, if a
cardiopulmonary exercise test is unavailable.16 As
expected, in our study, DW was higher in males
than in females, since males were heavier and
covered a longer 6MWD than females.
In this study, we found that both resting and
walking PR values were significantly higher in
females as compared to males. Previous studies
showed gender related differences in heart rate
and reported an increase in resting heart rate in
women.28,29 Additionally, Jones 21 reported higher
heart rates in women following submaximal ex-
ercise when compared to those of men.Baroreflex
heart rate regulation may be different between
women and men 30,31 and the effects of estrogen on
baroreflex regulation can also occur in humans.32
Lastly, the present study confirms the common
appreciation that in healthy subjects the 6MWT is a
submaximal test, since the maximal heart rate
achieved was an average 68%.
In this study, we found that the walking-induced
breathlessness was weakly related to after-walking
RR and maximum PR, but was not reliably predicted
by any demographic and anthropometric variables of
the subjects. We also observed a slight gender
difference in breathlessness perception, which lacked
statistical significance when corrected for heart rate
change while walking. Our results mainly support the
view that the underlying mechanisms of exertion
dyspnea are quite elusive, and that subjectivity is
inherently involved in the symptom. However, they
also suggest that in healthy subjects, walk-induced
dyspnea could be linked to the perception of both
walk-induced tachycardia and tachypnea.
In summary, this study provides reference values
for the 6MWT variables for Caucasian subjects
20–50 years old. Our results confirm the relevant
effect of anthropometric characteristics on walking
capacity and suggest that, when rating dyspnea,
the change in heart rate while walking should be
considered.Acknowledgment
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